Sanofi has a name for its in­gre­di­ents spin­off, taps Cen­tri­ent head Karl Rot­thi­er as first CEO

As part of CEO Paul Hud­son’s mis­sion to re­vamp the com­pa­ny’s strat­e­gy around on­col­o­gy and im­munol­o­gy R&D, Sanofi un­wrapped plans in Feb­ru­ary to hive off its lega­cy API busi­ness. But Sanofi wants to main­tain its EU her­itage for the new com­pa­ny, and now has a name and new leader to move the spin­off ahead.

Sanofi will name its ac­tive phar­ma­ceu­ti­cal in­gre­di­ents spin­off Eu­roAPI, a nod to the com­pa­ny’s roots in the EU and planned op­er­a­tions home base for what will be the sec­ond largest in­gre­di­ents pro­duc­er in the world, Sanofi said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER